Corvus Pharmaceuticals, Inc. Additional Paid in Capital, Common Stock
Corvus Pharmaceuticals, Inc. (CRVS) had Additional Paid in Capital, Common Stock of $472.79 million as of 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2025-11-04
- 2025-09-30: Additional Paid in Capital, Common Stock $472.79M.
- 2025-06-30: Additional Paid in Capital, Common Stock $471.18M.
- 2025-03-31: Additional Paid in Capital, Common Stock $432.39M.
- 2024-12-31: Additional Paid in Capital, Common Stock $430.86M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2025-09-30 | $472.79M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $471.18M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $432.39M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $430.86M 10-Q · filed 2025-11-04 |
| 2024-09-30 | $398.04M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $397.25M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $375.05M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $374.36M 10-K · filed 2025-03-25 |
| 2023-09-30 | $373.79M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $372.91M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $364.86M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $364.36M 10-K · filed 2024-03-19 |
| 2022-09-30 | $363.74M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $363.08M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $362.41M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $361.67M 10-K · filed 2023-03-28 |
| 2021-09-30 | $360.91M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $341.48M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $329.10M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $295.28M 10-K · filed 2022-03-10 |
| 2020-09-30 | $292.82M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $291.48M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $290.07M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $288.22M 10-K · filed 2021-03-25 |
| 2019-09-30 | $286.47M 10-Q · filed 2019-10-29 |
| 2019-06-30 | $284.71M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $282.80M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $280.84M 10-K · filed 2020-03-09 |
| 2018-09-30 | $278.84M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $276.88M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $275.10M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $208.41M 10-K · filed 2019-03-07 |
| 2017-09-30 | $205.35M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $203.72M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $202.19M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $200.71M 10-K · filed 2018-03-01 |
| 2016-09-30 | $199.65M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $198.38M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $190.36M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $440.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |